No Data
No Data
Anatara Lifesciences Embarks on Stage 2 of GaRP Trial for Treatment of Irritable Bowel Syndrome
Anatara Lifesciences (ASX: ANR) has initiated Stage 2 of a Phase II gastrointestinal re-programming (GaRP) trial to treat patients with irritable bowel syndrome (IBS).
Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%
Anatara Lifesciences (ASX:ANR) secured firm commitments to raise AU$1 million, before costs, via the placement of 25 million new shares, the company said in a Wednesday filing with the Australian bour
Anatara Lifesciences Opens GaRP Therapy Trial Extension to Treat Irritable Bowel Syndrome
Anatara Lifesciences (ASX: ANR) is inviting members of the public to register their interest in Stage 2 of a pivotal Phase II Australian clinical trial of their gastrointestinal reprogramming (GaRP) product in the treatment of irritable bowel syndrome (IBS).
Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial
Anatara Lifesciences (ASX:ANR) has begun recruiting patients for the second stage of its irritable bowel syndrome trial after receiving final ethics approvals, according to a Tuesday filing with the A
Anatara Lifesciences Raised Nealy AU$960,000 Via Entitlement Offer
Anatara Lifesciences (ASX:ANR) raised about AU$955,637 via a 2-for-5 entitlement offer at AU$0.022 per share. Funds raised will be for the second stage of the GaRP-IBS trial, according to a Thursday n
Anatara Lifesciences to Proceed to Stage II of IBS Drug Trial
Anatara Lifesciences (ASX:ANR) said it has met the study objectives of stage I of its gastrointestinal reprogramming (GaRP) medication trial, for irritable bowel syndrome (IBS). The Data Safety Monito
No Data